Does previous anti-thrombotic use affect the course of coronavirus disease-2019?
Istanbul Medical Journal
; 23(4):301-305, 2022.
Article
in English
| CAB Abstracts | ID: covidwho-2317856
ABSTRACT
Introduction:
Proinflammatory cytokines, produced as an immune response in severe acute respiratory syndrome-coronavirus 2 infection, activate the coagulation cascade as well. In this study, we investigated the difference in the clinical course of patients who had been already using anti-thrombotic therapy before coronavirus disease-2019 (COVID-19) for any reason compared to the group who had not.Methods:
In this retrospective, multicenter study;patients who were hospitalized between March 11 and July 1, 2020 were divided into two main groups as who had been on anti-thrombotic therapy for any indication use previously at the time of admission or who had not been on anti-thrombotic therapy at the time of admission, and their selected clinical parameters were compared.Results:
After analyzing the study population of 124 patients with a homogeneous distribution in terms of age and gender, the comparison of anti-thrombotic users and non-users showed no significant difference in hospitalization. There was a statistically significant decrease in mechanical ventilation apply rate, intensive care unit duration and mortality rate between the group using anti-thrombotic compared to the group not using it (p<0.05).Conclusion:
It has already been shown that COVID-19 patients are more prone to thromboembolic events as it activates the coagulation cascade with the cytokine storm it creates and thus the mortality of COVID-19 infection increases significantly. Parallel to this fact the results of our study demonstrated that using anti-thrombotic therapy for any reason may affect the bad prognosis of the disease positively.
Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210]; Human Immunology and Allergology [VV055]; Non-communicable Human Diseases and Injuries [VV600]; human diseases; coronavirus disease 2019; viral diseases; mortality; retrospective studies; clinical aspects; disease course; immune response; physiopathology; prognosis; chemokines; disease prevalence; fibrinolysis; thrombosis; Severe acute respiratory syndrome coronavirus 2; man; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; SARS-CoV-2; viral infections; death rate; clinical picture; disease progression; immunity reactions; immunological reactions; pathophysiology; blood clots
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Prognostic study
Language:
English
Journal:
Istanbul Medical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS